<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625362</url>
  </required_header>
  <id_info>
    <org_study_id>0417-HRW/2018</org_study_id>
    <nct_id>NCT03625362</nct_id>
  </id_info>
  <brief_title>Hydrogen-rich Water for Non-alchoholic Fatty Liver Disease</brief_title>
  <official_title>Effects of Hydrogen-rich Water on Liver Fat Accumulation, Blood Lipids and Body Fatness in Patients With Non-alchoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Novi Sad, Faculty of Sport and Physical Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Novi Sad, Faculty of Sport and Physical Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates how 4-week supplementation with hydrogen-rich water affects liver fat
      accumulation, blood lipid profiles and body composition in patients with non-alcoholic fatty
      liver disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder characterized by liver fat
      deposition due to causes other than excessive alcohol consumption. NAFLD can cause many liver
      dysfunction-related symptoms and signs, with the disease may progress to non-alcoholic
      steatohepatitis, a condition marked by liver inflammation, fibrosis and irreversible damage.
      NAFLD is usually accompanied by insulin resistance and obesity, with up to 30% of population
      in industrialized countries have NAFLD. While NAFLD is rapidly becoming the most common liver
      disease worldwide, its treatment remains elusive, and directed toward correction of the risk
      factors. Since metabolic impairment plays a major role in NAFLD pathogenesis, any agent that
      advance lipid and glucose metabolism could be appropriate to tackle this complex condition.
      Molecular hydrogen (H2) has recently emerged as a novel pro-metabolic agent that might
      positively affect liver health. Supplemental hydrogen improves blood lipid profiles and
      insulin resistance in overweight women, patients with type 2 diabetes, and in subjects with
      potential metabolic syndrome. In addition, drinking hydrogen-rich water reduces hepatic
      oxidative stress and alleviated fatty liver damage in rodents. However, no human studies so
      far evaluated its effectiveness to alter liver steatosis in patients with NAFLD. In this
      pilot trial, we analyze the effects of 4-week hydrogen-rich water intake on liver fat
      deposition, body composition and lab chemistry profiles in overweight patients suffering from
      NAFLD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver fat content</measure>
    <time_frame>Change from baseline liver triglycerides at 4 weeks</time_frame>
    <description>MRS spectra for liver triglycerides</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>Change from baseline total cholesterol at 4 weeks</time_frame>
    <description>Level of total cholesterol in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body fatness</measure>
    <time_frame>Change from baseline fat percentage at 4 weeks</time_frame>
    <description>Fat percentage evaluated by BIA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Hydrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 L of hydrogen-rich water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 L of tap water</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hydrogen</intervention_name>
    <description>Hydrogen-rich water</description>
    <arm_group_label>Hydrogen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tap water</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  Body mass index &gt; 25 kg/m2

          -  Free of major diseases besides NAFLD

          -  Must be able to give written informed consent

        Exclusion Criteria:

          -  Use of any dietary supplements within 4 weeks before study commences

          -  Abnormal values for lab clinical chemistry (&gt; 2 SD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Applied Bioenergetics Lab at Faculty of Sport and PE</name>
      <address>
        <city>Novi Sad</city>
        <state>Vojvodina</state>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSPE Applied Bioenergetics Lab</name>
      <address>
        <city>Novi Sad</city>
        <state>Vojvodina</state>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Serbia</country>
  </location_countries>
  <reference>
    <citation>Kajiyama S, Hasegawa G, Asano M, Hosoda H, Fukui M, Nakamura N, Kitawaki J, Imai S, Nakano K, Ohta M, Adachi T, Obayashi H, Yoshikawa T. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutr Res. 2008 Mar;28(3):137-43. doi: 10.1016/j.nutres.2008.01.008.</citation>
    <PMID>19083400</PMID>
  </reference>
  <reference>
    <citation>Nakao A, Toyoda Y, Sharma P, Evans M, Guthrie N. Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome-an open label pilot study. J Clin Biochem Nutr. 2010 Mar;46(2):140-9. doi: 10.3164/jcbn.09-100. Epub 2010 Feb 24.</citation>
    <PMID>20216947</PMID>
  </reference>
  <reference>
    <citation>Korovljev D, Trivic T, Drid P, Ostojic SM. Molecular hydrogen affects body composition, metabolic profiles, and mitochondrial function in middle-aged overweight women. Ir J Med Sci. 2018 Feb;187(1):85-89. doi: 10.1007/s11845-017-1638-4. Epub 2017 May 30.</citation>
    <PMID>28560519</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD will be shared via Institutional repository</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

